RheumaGen develops a class of cell and gene therapy treatments aimed at autoimmune diseases.
RheumaGen's investors include SPRIM Global Investments, Beyond Celiac Investments, William Taylor Nominees.
RheumaGen is headquartered in Aurora, United States.
RheumaGen develops a class of cell and gene therapy treatments aimed at autoimmune diseases.
RheumaGen is at the Series A stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"RheumaGen — Funding & Investors." VCBacked, December 22, 2025, https://www.vcbacked.co/company/rheumagen. Accessed August 16, 2026.
VCBacked. (2025). RheumaGen — Funding & Investors. Retrieved August 16, 2026, from https://www.vcbacked.co/company/rheumagen
{{cite web |title=RheumaGen — Funding & Investors |url=https://www.vcbacked.co/company/rheumagen |website=VCBacked |access-date=August 16, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated